Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xaluritamig - Amgen/Xencor

Next Previous
Drug Profile

Xaluritamig - Amgen/Xencor

Alternative Names: AMG-509

Latest Information Update: 02 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Xencor
  • Developer Amgen; BeOne Medicines; Xencor
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase I Ewing's sarcoma

Most Recent Events

  • 25 Mar 2026 Amgen plans a phase Ib trial in Prostate cancer (Metastatic disease, Hormone refractory, Second-line therapy or greater) (IV) in May 2026 (NCT07493512)
  • 16 Mar 2026 Phase-I clinical trials in Ewing's Sarcoma (In children, In adolescents, In adults, In the elderly, Second-line therapy or greater) in Australia, USA (IV) (NCT07297979)
  • 30 Jan 2026 Xaluritamig is still in preclinical development in Ewing's Sarcoma in USA (IV) (Amgen pipeline, January 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top